Dexcom (DXCM) Operating Expenses (2010 - 2026)

Dexcom (DXCM) has 17 years of Operating Expenses data on file, last reported at $495.0 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $495.0 million, up 8.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 5.3% YoY), and the FY2025 annual result was $1.9 billion, up 2.82% from the prior year.
• Operating Expenses rose to $495.0 million in Q1 2026 per DXCM's latest filing, from $469.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $495.0 million in Q1 2026 and troughed at $346.7 million in Q3 2022.
• A 5-year average of $435.7 million and a median of $441.8 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses decreased 11.89% in 2022, then climbed 20.51% in 2023.
• A 5-year view of Operating Expenses shows it stood at $415.9 million in 2022, then gained by 5.72% to $439.7 million in 2023, then advanced by 6.19% to $466.9 million in 2024, then rose by 0.6% to $469.7 million in 2025, then climbed by 5.39% to $495.0 million in 2026.
• Business Quant data shows DXCM's Operating Expenses at $495.0 million in Q1 2026, $469.7 million in Q4 2025, and $488.9 million in Q3 2025.